Michael P. Hay

7.3k citations

103 papers · 5.8k indexed · 1 hit paper · h-index 32

Impact in

Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
Biotechnology top 1%
- Cancer Research and Treatments

Papers in

Cancer Research 43
- Cancer, Hypoxia, and Metabolism 41
Organic Chemistry 33
- Synthesis and Biological Evaluation 14
- Click Chemistry and Applications 7

Co-authors: William R. Wilson William A. Denny Robert F. Anderson Frederik B. Pruijn Kevin O. Hicks S.S. Shinde Amato J. Giaccia Denise A. Chan
Journals: Journal of Medicinal Chemistry (13 papers)Journal of the American Chemical Society (7 papers)Molecules (5 papers)Cancer Research (4 papers)Biochemical Pharmacology (4 papers)
Partner nations: New Zealand United States United Kingdom

In The Last Decade

Michael P. Hay

100 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

Targeting hypoxia in cancer therapy 2011 · 2.6k citations

Peers

Countries citing papers authored by Michael P. Hay

Since Specialization

Citations

This map shows the geographic impact of Michael P. Hay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Hay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Hay more than expected).

Fields of papers citing papers by Michael P. Hay

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Hay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Hay. The network helps show where Michael P. Hay may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael P. Hay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael P. Hay Line = papers co-authored together Michael P. Hay links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Novel Prodrug Strategies for the Treatment of Tuberculosis Chemistry - An Asian Journal ·Christine Kim, Jiney Jose, Michael P. Hay, Peter J. Choi	2024	2
2	Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers Journal of Medicinal Chemistry ·Cho Rong Hong, Lydia P. Liew, Way W. Wong, Benjamin D. Dickson, Gary J. Cheng, Avik Shome, Rebecca Airey, Jagdish K. Jaiswal, Barbara Lipert, Stephen M. F. Jamieson, William R. Wilson, Michael P. Hay	2024	0
3	Megakaryocyte maturation involves activation of the adaptive unfolded protein response Genes to Cells ·Mifra Faiz, Maggie L. Kalev‐Zylinska, Caitlin Dunstan‐Harrison, Dean C. Singleton, Michael P. Hay, Elizabeth C. Ledgerwood	2024	1
4	Hypoxia-activated prodrugs of phenolic olaparib analogues for tumour-selective chemosensitisation RSC Medicinal Chemistry ·Way W. Wong, Sophia F. O'Brien-Gortner, Robert F. Anderson, William R. Wilson, Michael P. Hay, Benjamin D. Dickson	2023	2
5	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer Cancers ·Tet Woo Lee, Amy Lai, Julia Harms, Dean C. Singleton, Benjamin D. Dickson, Andrew Macann, Michael P. Hay, Stephen M. F. Jamieson	2020	23
6	Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia International Journal of Radiation Biology ·Tet Woo Lee, Way W. Wong, Benjamin D. Dickson, Barbara Lipert, Gary J. Cheng, Francis W. Hunter, Michael P. Hay, William R. Wilson	2019	37
7	Targeting growth hormone function: strategies and therapeutic applications Signal Transduction and Targeted Therapy ·Man Lu, Jack U. Flanagan, Ries J. Langley, Michael P. Hay, Jo K. Perry	2019	103
8	Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361 Biochemical Pharmacology ·Way W. Wong, Rosanna K. Jackson, Lydia P. Liew, Benjamin D. Dickson, Gary J. Cheng, Barbara Lipert, Yongchuan Gu, Francis W. Hunter, William R. Wilson, Michael P. Hay	2019	23
9	Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors Molecules ·Benjamin D. Dickson, Way W. Wong, William R. Wilson, Michael P. Hay	2019	13
10	Acridine Derivatives as Inhibitors of the IRE1α–XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma Molecular Cancer Therapeutics ·Dadi Jiang, Arvin B. Tam, Muthuraman Alagappan, Michael P. Hay, Aparna Gupta, Margaret M. Kozak, David E. Solow-Cordero, Pek Yee Lum, Nicholas Denko, Amato J. Giaccia, Quynh‐Thu Le, Maho Niwa, Albert C. Koong	2016	27
11	¹⁸F-EF5 PET Imaging as an Early Response Biomarker for the Hypoxia-Activated Prodrug SN30000 Combined with Radiation Treatment in a Non–Small Cell Lung Cancer Xenograft Model Journal of Nuclear Medicine ·Satish K. Chitneni, Gerald T. Bida, Hong Yuan, Gregory M. Palmer, Michael P. Hay, Thorsten Melcher, William R. Wilson, Michael R. Zalutsky, Mark W. Dewhirst	2013	32
12	The 2-Nitroimidazole EF5 Is a Biomarker for Oxidoreductases That Activate the Bioreductive Prodrug CEN-209 under Hypoxia Clinical Cancer Research ·Jingli Wang, Annika Foehrenbacher, Jiechuang Su, Rita Patel, Michael P. Hay, Kevin O. Hicks, William R. Wilson	2011	55
13	Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality Science Translational Medicine ·Denise A. Chan, Patrick D. Sutphin, Phuong Nguyen, Sandra Turcotte, Edwin W. Lai, Alice Banh, Gloria E. Reynolds, Jen‐Tsan Chi, Jason Wu, David E. Solow-Cordero, Muriel Bonnet, Jack U. Flanagan, Donna M. Bouley, Edward E. Graves, William A. Denny, Michael P. Hay, Amato J. Giaccia	2011	456
14	EF5 as a predictive biomarker for activation of the new hypoxia-targeting prodrug SN30000. Journal of Clinical Oncology ·Jie Wang, Annika Foehrenbacher, Jiechuang Su, Rita Patel, Michael P. Hay, Kevin O. Hicks, William R. Wilson	2011	2
15	SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells Bioorganic & Medicinal Chemistry ·Muriel Bonnet, Jack U. Flanagan, Denise A. Chan, Edwin W. Lai, Phuong Nguyen, Amato J. Giaccia, Michael P. Hay	2011	19
16	Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: Comparison with other hypoxia-activated prodrugs Biochemical Pharmacology ·Francis W. Hunter, Jingli Wang, Rita Patel, Huai‐Ling Hsu, Anthony J. Hickey, Michael P. Hay, William R. Wilson	2011	35
17	Pharmacokinetic/Pharmacodynamic Modeling Identifies SN30000 and SN29751 as Tirapazamine Analogues with Improved Tissue Penetration and Hypoxic Cell Killing in Tumors Clinical Cancer Research ·Kevin O. Hicks, Bronwyn G. Siim, Jagdish K. Jaiswal, Frederik B. Pruijn, Annie M. Fraser, Rita Patel, Alison Hogg, H.D. Sarath Liyanage, Mary J. Dorie, Jeremy Brown, William A. Denny, Michael P. Hay, William R. Wilson	2010	103
18	A novel molecule targeting VHL-deficient renal cell carcinoma that induces autophagic cell death Molecular Cancer Therapeutics ·Sandra Turcotte, Patrick D. Sutphin, Denise A. Chan, Michael P. Hay, William A. Denny, Amato J. Giaccia	2007	2
19	Use of Three-Dimensional Tissue Cultures to Model Extravascular Transport and Predict In Vivo Activity of Hypoxia-Targeted Anticancer Drugs JNCI Journal of the National Cancer Institute ·Kevin O. Hicks, Frederik B. Pruijn, Timothy W. Secomb, Michael P. Hay, Richard Hsu, Jeremy Brown, William A. Denny, Mark W. Dewhirst, William R. Wilson	2006	115
20	Effect of cell type and drug lipophilicity on the extravascular transport of small molecule anticancer drugs: tirapazamine analogs Cancer Research ·Kevin O. Hicks, Kashyap Patel, Frederik B. Pruijn, Michael P. Hay, William R. Wilson	2005	1

About Michael P. Hay

Michael P. Hay is a scholar working on Cancer Research, Organic Chemistry, Molecular Biology, Biotechnology and Pharmaceutical Science, having authored 103 papers that have together received 5.8k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (41 papers), Synthesis and Biological Evaluation (14 papers), Nanoplatforms for cancer theranostics (11 papers), Cancer therapeutics and mechanisms (10 papers), Epigenetics and DNA Methylation (9 papers), Chemical Synthesis and Analysis (7 papers), Click Chemistry and Applications (7 papers) and Cancer Research and Treatments (7 papers). The work is most often cited by research in Cancer Research (2.5k citations), Biotechnology (390 citations), Molecular Biology (2.9k citations), Organic Chemistry (998 citations) and Oncology (873 citations). Michael P. Hay has collaborated with scholars based in New Zealand, United States and United Kingdom. Frequent co-authors include William R. Wilson, William A. Denny, Robert F. Anderson, Frederik B. Pruijn, Kevin O. Hicks, S.S. Shinde, Amato J. Giaccia, Denise A. Chan, Sandra Turcotte and Patrick D. Sutphin. Their work appears in journals such as Journal of Medicinal Chemistry, Journal of the American Chemical Society, Molecules, Cancer Research and Biochemical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact